董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Richard W. Hamilton | 男 | Director | 58 | 8.42万美元 | 未持股 | 2021-03-29 |
| Sherri M. Brown | 女 | Director | 59 | 13.20万美元 | 未持股 | 2021-03-29 |
| Robert L. Van Nostrand | 男 | Chairman of the Board, Director | 63 | 9.86万美元 | 未持股 | 2021-03-29 |
| Oliver P. Peoples | 男 | President and Chief Executive Officer, Director | 63 | 108.18万美元 | 未持股 | 2021-03-29 |
| Anthony J. Sinskey | 男 | Director | 81 | 8.58万美元 | 未持股 | 2021-03-29 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Charles B. Haaser | 男 | Vice President, Finance, Chief Accounting Officer and Treasurer | 65 | 25.19万美元 | 未持股 | 2021-03-29 |
| Kristi D. Snell | 女 | Vice President, Research and Chief Science Officer | 53 | 57.93万美元 | 未持股 | 2021-03-29 |
| Oliver P. Peoples | 男 | President and Chief Executive Officer, Director | 63 | 108.18万美元 | 未持股 | 2021-03-29 |
| Lynne H. Brum | 女 | Vice President, Planning and Corporate Communications | 57 | 45.51万美元 | 未持股 | 2021-03-29 |
董事简历
中英对照 | 中文 | 英文- Richard W. Hamilton
-
RichardW.Hamilton博士于2017年3月加入Yield10Bioscience担任董事。从2002年到2016年，他曾担任Ceres，Inc.的首席执行官兼董事会成员，此前曾于1998年至2002年担任谷神星的首席财务官。除了在Ceres担任领导角色外，Hamilton博士还曾在Keck Graduate Institute Advisory Council任职，他是可持续生物质生产理事会的创始成员。他曾任职于美国能源部的生物质研究与开发技术咨询委员会，并一直活跃于生物技术行业组织，在那里他曾担任该组织的副主席，担任其食品和农业管理委员会主席，并担任其他领导职务。从1992年到1997年，Hamilton博士是Oxford Bioscience Partners的负责人，从1993年到1996年，他是波士顿MVP Ventures的合伙人。Hamilton从1990年到1991年担任Harvard Medical School Howard Hughes Medical Institute研究员。Hamilton博士在圣劳伦斯大学（St.Lawrence University）获得生物学学士学位，并持有范德堡大学（Vanderbilt University）分子生物学博士学位。
Richard W. Hamilton joined Yield10 as a Director in March 2017 and serves as Chairman of the Nominating and Corporate Governance Committee. From 2002 to 2016 he served as Chief Executive Officer and as a member of the board of directors at Ceres, Inc., after previously serving as Ceres’ Chief Financial Officer from 1998 to 2002. In addition to his leadership role at Ceres, Dr. Hamilton has served on the Keck Graduate Institute Advisory Council and was a founding member of the Council for Sustainable Biomass Production. He has served on the U.S. Department of Energy's Biomass Research and Development Technical Advisory Committee and has been active in the Biotechnology Industry Organization, where he has served as Vice Chairman of the organization, chaired its Food and Agriculture Governing Board and served in other leadership roles. From 1992 to 1997 Dr. Hamilton was a Principal at Oxford Bioscience Partners, and from 1993 to 1996 he was an Associate at Boston-based MVP Ventures. From 1990 to 1991 Dr. Hamilton was a Howard Hughes Medical Institute Research Fellow at Harvard Medical School. Dr. Hamilton received a B.S. in biology from St. Lawrence University and holds a Ph.D. in molecular biology from Vanderbilt University. - RichardW.Hamilton博士于2017年3月加入Yield10Bioscience担任董事。从2002年到2016年，他曾担任Ceres，Inc.的首席执行官兼董事会成员，此前曾于1998年至2002年担任谷神星的首席财务官。除了在Ceres担任领导角色外，Hamilton博士还曾在Keck Graduate Institute Advisory Council任职，他是可持续生物质生产理事会的创始成员。他曾任职于美国能源部的生物质研究与开发技术咨询委员会，并一直活跃于生物技术行业组织，在那里他曾担任该组织的副主席，担任其食品和农业管理委员会主席，并担任其他领导职务。从1992年到1997年，Hamilton博士是Oxford Bioscience Partners的负责人，从1993年到1996年，他是波士顿MVP Ventures的合伙人。Hamilton从1990年到1991年担任Harvard Medical School Howard Hughes Medical Institute研究员。Hamilton博士在圣劳伦斯大学（St.Lawrence University）获得生物学学士学位，并持有范德堡大学（Vanderbilt University）分子生物学博士学位。
- Richard W. Hamilton joined Yield10 as a Director in March 2017 and serves as Chairman of the Nominating and Corporate Governance Committee. From 2002 to 2016 he served as Chief Executive Officer and as a member of the board of directors at Ceres, Inc., after previously serving as Ceres’ Chief Financial Officer from 1998 to 2002. In addition to his leadership role at Ceres, Dr. Hamilton has served on the Keck Graduate Institute Advisory Council and was a founding member of the Council for Sustainable Biomass Production. He has served on the U.S. Department of Energy's Biomass Research and Development Technical Advisory Committee and has been active in the Biotechnology Industry Organization, where he has served as Vice Chairman of the organization, chaired its Food and Agriculture Governing Board and served in other leadership roles. From 1992 to 1997 Dr. Hamilton was a Principal at Oxford Bioscience Partners, and from 1993 to 1996 he was an Associate at Boston-based MVP Ventures. From 1990 to 1991 Dr. Hamilton was a Howard Hughes Medical Institute Research Fellow at Harvard Medical School. Dr. Hamilton received a B.S. in biology from St. Lawrence University and holds a Ph.D. in molecular biology from Vanderbilt University.
- Sherri M. Brown
-
Sherri M.Brown于2020年2月加入Yield10担任董事，并担任科学和技术委员会主席。Brown博士此前自2018年12月起担任公司的特别商业和技术顾问。自2017年以来，布朗博士一直担任Yield Lab（位于圣路易斯的全球农业食品科技加速器）的董事总经理。此前，她曾在孟山都公司担任多个领导职位，涉及新产品的开发和全球商业化，包括油菜籽、大豆和玉米的生物技术特性，任职28年。2014年至2017年，她担任Monsanto科学战略副总裁。在此之前，她曾担任全球商业技术/产品开发的副总裁（从2008年到2014年），在那里她负责评估和启动种子和特性管道，包括八个新的生物技术特性。此外，她曾担任技术副总裁，负责全球玉米业务（1999年至2004年）和技术副总裁，负责油籽业务团队（1998年至1999年）。布朗博士在印第安纳大学布鲁明顿分校获得博士学位，主修遗传学/分子、细胞和发育生物学。她在密歇根州霍普学院（Hope College，Holland）获得了学士学位，主修生物和化学。
Sherri M. Brown joined Yield10 as a Director in February 2020 and serves as Chair of the Science and Technology Committee. Dr. Brown previously served as a Special Commercial and Technical Advisor to the Company since December 2018. Since 2017 Dr. Brown has served as a managing director of The Yield Lab, a global agrifood tech accelerator based in St. Louis. She previously served in several leadership positions involving the development and global commercialization of new products including biotechnology traits for canola, soybean and corn at Monsanto Company for 28 years. She served as Vice President, Science Strategy at Monsanto from 2014 to 2017. Prior to that, she was Vice President, Global Commercial Technology/Product Development, from 2008 to 2014 where she was responsible for evaluating and launching the seed and trait pipeline, including eight new biotech traits. In addition, she was Vice President, Technology, Global Corn Business 1999-2004 and Vice President, Technology, Oilseeds Business team (1998-1999). Dr. Brown earned a Ph.D. at Indiana University, Bloomington, IN with a major in Genetics/Molecular, Cellular and Developmental Biology. She earned a B.S. at Hope College, Holland, MI with a double major in Biology and Chemistry. - Sherri M.Brown于2020年2月加入Yield10担任董事，并担任科学和技术委员会主席。Brown博士此前自2018年12月起担任公司的特别商业和技术顾问。自2017年以来，布朗博士一直担任Yield Lab（位于圣路易斯的全球农业食品科技加速器）的董事总经理。此前，她曾在孟山都公司担任多个领导职位，涉及新产品的开发和全球商业化，包括油菜籽、大豆和玉米的生物技术特性，任职28年。2014年至2017年，她担任Monsanto科学战略副总裁。在此之前，她曾担任全球商业技术/产品开发的副总裁（从2008年到2014年），在那里她负责评估和启动种子和特性管道，包括八个新的生物技术特性。此外，她曾担任技术副总裁，负责全球玉米业务（1999年至2004年）和技术副总裁，负责油籽业务团队（1998年至1999年）。布朗博士在印第安纳大学布鲁明顿分校获得博士学位，主修遗传学/分子、细胞和发育生物学。她在密歇根州霍普学院（Hope College，Holland）获得了学士学位，主修生物和化学。
- Sherri M. Brown joined Yield10 as a Director in February 2020 and serves as Chair of the Science and Technology Committee. Dr. Brown previously served as a Special Commercial and Technical Advisor to the Company since December 2018. Since 2017 Dr. Brown has served as a managing director of The Yield Lab, a global agrifood tech accelerator based in St. Louis. She previously served in several leadership positions involving the development and global commercialization of new products including biotechnology traits for canola, soybean and corn at Monsanto Company for 28 years. She served as Vice President, Science Strategy at Monsanto from 2014 to 2017. Prior to that, she was Vice President, Global Commercial Technology/Product Development, from 2008 to 2014 where she was responsible for evaluating and launching the seed and trait pipeline, including eight new biotech traits. In addition, she was Vice President, Technology, Global Corn Business 1999-2004 and Vice President, Technology, Oilseeds Business team (1998-1999). Dr. Brown earned a Ph.D. at Indiana University, Bloomington, IN with a major in Genetics/Molecular, Cellular and Developmental Biology. She earned a B.S. at Hope College, Holland, MI with a double major in Biology and Chemistry.
- Robert L. Van Nostrand
-
Robert L. Van Nostrand，自2014年1月Van Nostrand先生担任公司董事，从2010年1月至2010年7月Van Nostrand先生曾担任AUREON生物科学公司（Aureon Biosciences, Inc.）执行副总裁兼首席财务官，这是一家私人病理生命科学公司；在加入AUREON生物科学（Aureon Biosciences）之前，从2007年7月至2008年9月公司被收购时，Van Nostrand先生担任AGI Dermatics公司（AGI Dermatics, Inc.）执行副总裁兼首席财务官，这是一家私人生物技术公司；从2005年5月至2007年7月Van Nostrand先生担任OSI制药公司（OSI Pharmaceuticals, Inc.）副总裁兼首席财务官，这是一家公开上市的生物技术公司，在这里，他曾从1996年12月到2005年5月担任高级副总裁兼首席财务官，之前担任财务和行政副总裁。从1992年3月至2005年5月他还曾担任OSI的财务主管，从1995年3月至2004年1月Van Nostrand先生担任秘书，在1986年9月Van Nostrand先生担任总监和首席会计官，加入OSI前，Van Nostrand先生担任会计师事务所塔奇·罗斯公司（Touche Ross & Co。）（现名德勤（Deloitte））的管理职位。Van Nostrand先生作为一家公开上市的生物技术公司Metabolix公司（Metabolix, Inc.）董事会主席及审计委员会主席。Van Nostrand先生还担任一家公开上市的生物技术公司艾琪尔顿制药公司（Achillion Pharmaceuticals, Inc.）董事会主席及审计委员会主席。他还在纽约生物医学研究联盟（the Biomedical Research Alliance of New York），一家提供临床试验服务的私营公司董事会任职。Van Nostrand先生是纽约生物技术协会（the New York Biotechnology Association）董事会前任主席以及成员，并在法明代尔大学（ Farmingdale University）基金会董事会任职。此前，Van Nostrand先生在Apex BioVentures公司（Apex Bioventures, Inc.）董事会任职，这是一家专注于生命科学拥有特殊目的收购公司。Van Nostrand先生获得长岛大学（Long Island University）纽约分校的会计学士学位。他是一名注册会计师。
Robert L. Van Nostrand is a consultant who has served as Chairman of the Board since October 2013 and as a Director since October 2006. From January 2010 to July 2010 he was Executive Vice President and Chief Financial Officer of Aureon Laboratories, Inc. From July 2007 until September 2008 Mr. Van Nostrand served as Executive Vice President and Chief Financial Officer of AGI Dermatics, Inc. Mr. Van Nostrand was with OSI Pharmaceuticals, Inc. from 1986 to 2007 serving as Senior Vice President and Chief Compliance Officer from May 2005 until July 2007 and as the Vice President and Chief Financial Officer from 1996 through 2005. Prior to joining OSI, Mr. Van Nostrand was in a managerial position with Touche Ross & Co. currently Deloitte. Mr. Van Nostrand serves on the board of directors and is Chairman of the audit committee of Intra-Cellular Therapies, Inc. (since January 2014), serves on the boards of directors of Enumeral Biomedical, Inc. (since December 2014) and the Biomedical Research Alliance of New York (BRANY) (since 2011), and served on the board of directors and as Chairman of the audit committee of Apex Bioventures, Inc. from 2006 to 2009. Mr. Van Nostrand received a B.S. in Accounting from Long Island University, New York, completed advanced management studies at the Wharton School, and he is a Certified Public Accountant. - Robert L. Van Nostrand，自2014年1月Van Nostrand先生担任公司董事，从2010年1月至2010年7月Van Nostrand先生曾担任AUREON生物科学公司（Aureon Biosciences, Inc.）执行副总裁兼首席财务官，这是一家私人病理生命科学公司；在加入AUREON生物科学（Aureon Biosciences）之前，从2007年7月至2008年9月公司被收购时，Van Nostrand先生担任AGI Dermatics公司（AGI Dermatics, Inc.）执行副总裁兼首席财务官，这是一家私人生物技术公司；从2005年5月至2007年7月Van Nostrand先生担任OSI制药公司（OSI Pharmaceuticals, Inc.）副总裁兼首席财务官，这是一家公开上市的生物技术公司，在这里，他曾从1996年12月到2005年5月担任高级副总裁兼首席财务官，之前担任财务和行政副总裁。从1992年3月至2005年5月他还曾担任OSI的财务主管，从1995年3月至2004年1月Van Nostrand先生担任秘书，在1986年9月Van Nostrand先生担任总监和首席会计官，加入OSI前，Van Nostrand先生担任会计师事务所塔奇·罗斯公司（Touche Ross & Co。）（现名德勤（Deloitte））的管理职位。Van Nostrand先生作为一家公开上市的生物技术公司Metabolix公司（Metabolix, Inc.）董事会主席及审计委员会主席。Van Nostrand先生还担任一家公开上市的生物技术公司艾琪尔顿制药公司（Achillion Pharmaceuticals, Inc.）董事会主席及审计委员会主席。他还在纽约生物医学研究联盟（the Biomedical Research Alliance of New York），一家提供临床试验服务的私营公司董事会任职。Van Nostrand先生是纽约生物技术协会（the New York Biotechnology Association）董事会前任主席以及成员，并在法明代尔大学（ Farmingdale University）基金会董事会任职。此前，Van Nostrand先生在Apex BioVentures公司（Apex Bioventures, Inc.）董事会任职，这是一家专注于生命科学拥有特殊目的收购公司。Van Nostrand先生获得长岛大学（Long Island University）纽约分校的会计学士学位。他是一名注册会计师。
- Robert L. Van Nostrand is a consultant who has served as Chairman of the Board since October 2013 and as a Director since October 2006. From January 2010 to July 2010 he was Executive Vice President and Chief Financial Officer of Aureon Laboratories, Inc. From July 2007 until September 2008 Mr. Van Nostrand served as Executive Vice President and Chief Financial Officer of AGI Dermatics, Inc. Mr. Van Nostrand was with OSI Pharmaceuticals, Inc. from 1986 to 2007 serving as Senior Vice President and Chief Compliance Officer from May 2005 until July 2007 and as the Vice President and Chief Financial Officer from 1996 through 2005. Prior to joining OSI, Mr. Van Nostrand was in a managerial position with Touche Ross & Co. currently Deloitte. Mr. Van Nostrand serves on the board of directors and is Chairman of the audit committee of Intra-Cellular Therapies, Inc. (since January 2014), serves on the boards of directors of Enumeral Biomedical, Inc. (since December 2014) and the Biomedical Research Alliance of New York (BRANY) (since 2011), and served on the board of directors and as Chairman of the audit committee of Apex Bioventures, Inc. from 2006 to 2009. Mr. Van Nostrand received a B.S. in Accounting from Long Island University, New York, completed advanced management studies at the Wharton School, and he is a Certified Public Accountant.
- Oliver P. Peoples
-
Oliver P. Peoples， 他是Metabolix的联合创始人。他自2000年1月担任公司的首席科学官。之前，他担任公司的研发部副总裁。他自1992年成为董事。在创立Metabolix之前，他是麻省理工学院生物系的一位研究科学家。他在麻省理工学院的研究建立了操作管理菌和植物的基本工具和方法，用以生产聚羟基烷酸酯。他在苏格兰的University of Aberdeen获得了分子生物学博士学位。
Oliver P. Peoples has served as our President and Chief Executive Officer since October 2016. He was co-founder of Yield10. He served as our Chief Scientific Officer starting in January 2000 and was previously our Vice President of Research and Development. Dr. Peoples has served as a Director since June 1992. Before founding the Company, Dr. Peoples was a research scientist with the Department of Biology at MIT. The research carried out by Dr. Peoples at MIT established the fundamental tools and methods for engineering bacteria and plants to produce polyhydroxyalkanoates. Dr. Peoples received a Ph.D. in Molecular Biology from the University of Aberdeen, Scotland. - Oliver P. Peoples， 他是Metabolix的联合创始人。他自2000年1月担任公司的首席科学官。之前，他担任公司的研发部副总裁。他自1992年成为董事。在创立Metabolix之前，他是麻省理工学院生物系的一位研究科学家。他在麻省理工学院的研究建立了操作管理菌和植物的基本工具和方法，用以生产聚羟基烷酸酯。他在苏格兰的University of Aberdeen获得了分子生物学博士学位。
- Oliver P. Peoples has served as our President and Chief Executive Officer since October 2016. He was co-founder of Yield10. He served as our Chief Scientific Officer starting in January 2000 and was previously our Vice President of Research and Development. Dr. Peoples has served as a Director since June 1992. Before founding the Company, Dr. Peoples was a research scientist with the Department of Biology at MIT. The research carried out by Dr. Peoples at MIT established the fundamental tools and methods for engineering bacteria and plants to produce polyhydroxyalkanoates. Dr. Peoples received a Ph.D. in Molecular Biology from the University of Aberdeen, Scotland.
- Anthony J. Sinskey
-
Anthony J. Sinskey， 他是Metabolix的联合创始人，并自1992年6月担任董事。从1968年至今，他一直在麻省理工学院（MIT）任教。在麻省理工学院，目前他担任生物学系的微生物学教授，哈佛 - 麻省理工学院卫生科学与技术工程项目系统部（Harvard-MIT Health Sciences and Technology Program Engineering Systems Division）的健康科学与技术教授，也是生物医药创新中心（Center for Biomedical Innovation）的教员主任。他任职于Tepha的董事会，监督“某些关系及相关人士交易”。他在University of Illinois获得了理学学士学位，并且在麻省理工学院获得了博士学位。
Anthony J. Sinskey has served as a Director since June 1992 was a co-founder of Yield10 and serves as Chairman of the Compensation Committee. From 1968 to present, Dr. Sinskey has been on the faculty of MIT. Currently at MIT, he serves as Professor of Microbiology in the Department of Biology, as well as faculty director of the Center for Biomedical Innovation. Dr. Sinskey was a co-founder and served on the board of directors of Merrimack Pharmaceuticals, Inc. from 1999 until January 2015. Dr. Sinskey received a B.S. from the University of Illinois and a Sc.D. from MIT. - Anthony J. Sinskey， 他是Metabolix的联合创始人，并自1992年6月担任董事。从1968年至今，他一直在麻省理工学院（MIT）任教。在麻省理工学院，目前他担任生物学系的微生物学教授，哈佛 - 麻省理工学院卫生科学与技术工程项目系统部（Harvard-MIT Health Sciences and Technology Program Engineering Systems Division）的健康科学与技术教授，也是生物医药创新中心（Center for Biomedical Innovation）的教员主任。他任职于Tepha的董事会，监督“某些关系及相关人士交易”。他在University of Illinois获得了理学学士学位，并且在麻省理工学院获得了博士学位。
- Anthony J. Sinskey has served as a Director since June 1992 was a co-founder of Yield10 and serves as Chairman of the Compensation Committee. From 1968 to present, Dr. Sinskey has been on the faculty of MIT. Currently at MIT, he serves as Professor of Microbiology in the Department of Biology, as well as faculty director of the Center for Biomedical Innovation. Dr. Sinskey was a co-founder and served on the board of directors of Merrimack Pharmaceuticals, Inc. from 1999 until January 2015. Dr. Sinskey received a B.S. from the University of Illinois and a Sc.D. from MIT.
高管简历
中英对照 | 中文 | 英文- Charles B. Haaser
Charles B. Haaser自2014年11月3日起担任公司首席会计官，自2008年起担任公司企业总监。Haaser在会计和金融领域有着30多年的经验，主要为公共上市美国公司服务。加入Metabolix之前，Haaser从2006年到2008年担任Indevus Pharmaceuticals, Inc.企业总监。他从1998年到2006年担任ABIOMED, Inc.企业总监和首席会计官；2003年到2006年担任ABIOMED代理首席财务官。Haaser从1997年到1998年担任Technical Communications Corporation总监；1986年到1997年担任ISI Systems, Inc.金融主管；1984年到1986年担任Price Waterhouse LLP 现名为PricewaterhouseCoopers LLP商业审计部门审计员。Haaser持有the University of Notre Dame工商管理金融学士学位；Northeastern University工商管理硕士学位；以及Bentley University税收法理学硕士学位。Haaser于1997年成为一名注册会计师。
Charles B. Haaser has served as the Company's Vice President, Finance, Chief Accounting Officer and Treasurer since October 2016 after having served as Chief Accounting Officer and Treasurer since November 2014 and its Corporate Controller since 2008. Mr. Haaser has more than thirty-five years of experience in accounting and finance, primarily working for publicly traded U.S. companies. Before joining Yield10 Mr. Haaser was the Corporate Controller of Indevus Pharmaceuticals, Inc. from 2006 to 2008. He was the Corporate Controller and Principal Accounting Officer at ABIOMED, Inc. from 1998 to 2006 and additionally served as ABIOMED's Chief Financial Officer from 2003 to 2006. From 1997 to 1998 Mr. Haaser was Controller for Technical Communications Corporation and from 1986 to 1997 was the Director of Finance at ISI Systems, Inc. From 1984 to 1986 Mr. Haaser was an auditor in the commercial audit division of Price Waterhouse LLP now PricewaterhouseCoopers LLP and from 1978 to 1982 he served on active duty in the United States Navy as a commissioned officer. Mr. Haaser received a bachelor's degree in business administration (finance) from the University of Notre Dame, an MBA from Northeastern University and a Masters of Science in Taxation from Bentley University. Mr. Haaser became a Certified Public Accountant in 1997.- Charles B. Haaser自2014年11月3日起担任公司首席会计官，自2008年起担任公司企业总监。Haaser在会计和金融领域有着30多年的经验，主要为公共上市美国公司服务。加入Metabolix之前，Haaser从2006年到2008年担任Indevus Pharmaceuticals, Inc.企业总监。他从1998年到2006年担任ABIOMED, Inc.企业总监和首席会计官；2003年到2006年担任ABIOMED代理首席财务官。Haaser从1997年到1998年担任Technical Communications Corporation总监；1986年到1997年担任ISI Systems, Inc.金融主管；1984年到1986年担任Price Waterhouse LLP 现名为PricewaterhouseCoopers LLP商业审计部门审计员。Haaser持有the University of Notre Dame工商管理金融学士学位；Northeastern University工商管理硕士学位；以及Bentley University税收法理学硕士学位。Haaser于1997年成为一名注册会计师。
- Charles B. Haaser has served as the Company's Vice President, Finance, Chief Accounting Officer and Treasurer since October 2016 after having served as Chief Accounting Officer and Treasurer since November 2014 and its Corporate Controller since 2008. Mr. Haaser has more than thirty-five years of experience in accounting and finance, primarily working for publicly traded U.S. companies. Before joining Yield10 Mr. Haaser was the Corporate Controller of Indevus Pharmaceuticals, Inc. from 2006 to 2008. He was the Corporate Controller and Principal Accounting Officer at ABIOMED, Inc. from 1998 to 2006 and additionally served as ABIOMED's Chief Financial Officer from 2003 to 2006. From 1997 to 1998 Mr. Haaser was Controller for Technical Communications Corporation and from 1986 to 1997 was the Director of Finance at ISI Systems, Inc. From 1984 to 1986 Mr. Haaser was an auditor in the commercial audit division of Price Waterhouse LLP now PricewaterhouseCoopers LLP and from 1978 to 1982 he served on active duty in the United States Navy as a commissioned officer. Mr. Haaser received a bachelor's degree in business administration (finance) from the University of Notre Dame, an MBA from Northeastern University and a Masters of Science in Taxation from Bentley University. Mr. Haaser became a Certified Public Accountant in 1997.
- Kristi D. Snell
KristiD.Snell博士于2016年10月被任命为Vice President，研究和首席科学官，同时过渡到将10Bioscience作为公司的核心业务。Snell博士于1997年加入公司，她自公司成立以来一直领导植物科学研究计划。她曾在该公司担任多个职位，包括2013年7月至2016年10月担任Vice President、研究和生物技术，2014年4月至今担任该公司在加拿大的全资子公司Metabolix Oilseeds的总裁。Snell博士拥有超过20年的相关经验，是生产新颖产品和提高植物产量的植物和微生物代谢工程行业公认的专家。Snell博士在密歇根大学（University of Michigan）获得化学理学学士学位，并在普渡大学（Purdue University）获得有机化学博士学位，在那里她从事代谢工程策略，以增加流向工业产品的碳流量。Snell博士在麻省理工学院（MIT）进行生物化学和代谢工程的博士后研究。
Kristi D. Snell was named Vice President, Research and Chief Science Officer in October 2016 in conjunction with the transition to Yield10 as the Company’s core business. Dr. Snell joined the Company in 1997 and she has led the plant science research program since its inception. She has held a number of positions with the Company, including Vice President, Research and Biotechnology from July 2013 until October 2016 and President of Metabolix Oilseeds, the Company's wholly owned Canadian subsidiary, from April 2014 to present. Dr. Snell has more than 20 years of relevant experience and is an industry recognized expert in metabolic engineering of plants and microbes for the production of novel products and increased plant yield. Dr. Snell received a Bachelor of Science degree in Chemistry from the University of Michigan, and a Ph.D. in Organic Chemistry from Purdue University where she worked on metabolic engineering strategies to increase carbon flow to industrial products. Dr. Snell conducted her post-doctoral research at MIT in biochemistry and metabolic engineering.- KristiD.Snell博士于2016年10月被任命为Vice President，研究和首席科学官，同时过渡到将10Bioscience作为公司的核心业务。Snell博士于1997年加入公司，她自公司成立以来一直领导植物科学研究计划。她曾在该公司担任多个职位，包括2013年7月至2016年10月担任Vice President、研究和生物技术，2014年4月至今担任该公司在加拿大的全资子公司Metabolix Oilseeds的总裁。Snell博士拥有超过20年的相关经验，是生产新颖产品和提高植物产量的植物和微生物代谢工程行业公认的专家。Snell博士在密歇根大学（University of Michigan）获得化学理学学士学位，并在普渡大学（Purdue University）获得有机化学博士学位，在那里她从事代谢工程策略，以增加流向工业产品的碳流量。Snell博士在麻省理工学院（MIT）进行生物化学和代谢工程的博士后研究。
- Kristi D. Snell was named Vice President, Research and Chief Science Officer in October 2016 in conjunction with the transition to Yield10 as the Company’s core business. Dr. Snell joined the Company in 1997 and she has led the plant science research program since its inception. She has held a number of positions with the Company, including Vice President, Research and Biotechnology from July 2013 until October 2016 and President of Metabolix Oilseeds, the Company's wholly owned Canadian subsidiary, from April 2014 to present. Dr. Snell has more than 20 years of relevant experience and is an industry recognized expert in metabolic engineering of plants and microbes for the production of novel products and increased plant yield. Dr. Snell received a Bachelor of Science degree in Chemistry from the University of Michigan, and a Ph.D. in Organic Chemistry from Purdue University where she worked on metabolic engineering strategies to increase carbon flow to industrial products. Dr. Snell conducted her post-doctoral research at MIT in biochemistry and metabolic engineering.
- Oliver P. Peoples
Oliver P. Peoples， 他是Metabolix的联合创始人。他自2000年1月担任公司的首席科学官。之前，他担任公司的研发部副总裁。他自1992年成为董事。在创立Metabolix之前，他是麻省理工学院生物系的一位研究科学家。他在麻省理工学院的研究建立了操作管理菌和植物的基本工具和方法，用以生产聚羟基烷酸酯。他在苏格兰的University of Aberdeen获得了分子生物学博士学位。
Oliver P. Peoples has served as our President and Chief Executive Officer since October 2016. He was co-founder of Yield10. He served as our Chief Scientific Officer starting in January 2000 and was previously our Vice President of Research and Development. Dr. Peoples has served as a Director since June 1992. Before founding the Company, Dr. Peoples was a research scientist with the Department of Biology at MIT. The research carried out by Dr. Peoples at MIT established the fundamental tools and methods for engineering bacteria and plants to produce polyhydroxyalkanoates. Dr. Peoples received a Ph.D. in Molecular Biology from the University of Aberdeen, Scotland.- Oliver P. Peoples， 他是Metabolix的联合创始人。他自2000年1月担任公司的首席科学官。之前，他担任公司的研发部副总裁。他自1992年成为董事。在创立Metabolix之前，他是麻省理工学院生物系的一位研究科学家。他在麻省理工学院的研究建立了操作管理菌和植物的基本工具和方法，用以生产聚羟基烷酸酯。他在苏格兰的University of Aberdeen获得了分子生物学博士学位。
- Oliver P. Peoples has served as our President and Chief Executive Officer since October 2016. He was co-founder of Yield10. He served as our Chief Scientific Officer starting in January 2000 and was previously our Vice President of Research and Development. Dr. Peoples has served as a Director since June 1992. Before founding the Company, Dr. Peoples was a research scientist with the Department of Biology at MIT. The research carried out by Dr. Peoples at MIT established the fundamental tools and methods for engineering bacteria and plants to produce polyhydroxyalkanoates. Dr. Peoples received a Ph.D. in Molecular Biology from the University of Aberdeen, Scotland.
- Lynne H. Brum
Lynne H. Brum，她自2011年11月担任公司副总裁，负责市场营销和企业传播。在加入Metabolix之前，2010年至2011年，她是一个通信顾问，曾担任过不同的职位，包括在Seidler Bernstein担任自由职业项目主管。2007年至2009年，她在Porter Novelli Life Sciences（全球公关公司Porter Novelli International的子公司）担任执行副总裁。在此之前，1994年至2007年，她在Vertex Pharmaceuticals担任过不同的职位，包括战略沟通的副总裁，负责企业传讯，投资者关系和品牌管理。她在Feinstein Kean Healthcare担任过副总裁，也曾是Biogen（现Biogen Idec）的通信团队成员。她在Wellesley College获得了生物科学学士学位，并且在Simmons College的管理学院获得了工商管理硕士学位。
Lynne H. Brum has served as Vice President, Planning and Communications since October 2016. She joined the Company in November 2011 as Vice President, Marketing and Corporate Communications. Prior to joining the Company, in 2010 to 2011 she was a communications consultant and served in various roles including as a freelance project director for Seidler Bernstein Inc. Ms. Brum served from 2007 to 2009 as an Executive Vice President at Porter Novelli Life Sciences, a subsidiary of global PR firm, Porter Novelli International. Prior to that, Ms. Brum was responsible for corporate communications, investor relations and brand management for Vertex Pharmaceuticals, Inc. from 1994 to 2007 in various positions, including Vice President of Strategic Communications.- Lynne H. Brum，她自2011年11月担任公司副总裁，负责市场营销和企业传播。在加入Metabolix之前，2010年至2011年，她是一个通信顾问，曾担任过不同的职位，包括在Seidler Bernstein担任自由职业项目主管。2007年至2009年，她在Porter Novelli Life Sciences（全球公关公司Porter Novelli International的子公司）担任执行副总裁。在此之前，1994年至2007年，她在Vertex Pharmaceuticals担任过不同的职位，包括战略沟通的副总裁，负责企业传讯，投资者关系和品牌管理。她在Feinstein Kean Healthcare担任过副总裁，也曾是Biogen（现Biogen Idec）的通信团队成员。她在Wellesley College获得了生物科学学士学位，并且在Simmons College的管理学院获得了工商管理硕士学位。
- Lynne H. Brum has served as Vice President, Planning and Communications since October 2016. She joined the Company in November 2011 as Vice President, Marketing and Corporate Communications. Prior to joining the Company, in 2010 to 2011 she was a communications consultant and served in various roles including as a freelance project director for Seidler Bernstein Inc. Ms. Brum served from 2007 to 2009 as an Executive Vice President at Porter Novelli Life Sciences, a subsidiary of global PR firm, Porter Novelli International. Prior to that, Ms. Brum was responsible for corporate communications, investor relations and brand management for Vertex Pharmaceuticals, Inc. from 1994 to 2007 in various positions, including Vice President of Strategic Communications.